GET DAILY SIGNALSOvid Therapeutics (OVID): A Look at Its Neuroscience-Focused Biotech Pipeline
Key Takeaways
- OVID represents the Nasdaq listing for Ovid Therapeutics Inc., a New York-based clinical-stage biopharmaceutical firm targeting neurological and neuropsychiatric conditions.
- The company advances small-molecule therapies aimed at rare epilepsies, seizures, and psychosis, centered on its OV329 candidate and KCC2 direct activator initiatives.
- Founded in 2014 by Dr. Jeremy Levin and Dr. Matthew During, Ovid currently has no approved products on the market and therefore reports minimal revenue.
- Operations are financed mainly through equity offerings, partnerships, and licensing arrangements instead of product sales.
- Investors track OVID for its distinct neuroscience pipeline while recognizing the elevated risks common to early-stage drug development.
Company Overview
Ovid Therapeutics Inc. operates as a clinical-stage biopharmaceutical company focused on creating treatments for brain disorders that still lack effective options. Listed on the Nasdaq under the ticker OVID, the firm directs its efforts toward neurological and neuropsychiatric issues linked to heightened neural activity, such as rare epilepsies, seizures that resist standard drugs, and certain psychotic conditions. With no commercial products yet, the company functions essentially as a pipeline-driven enterprise where progress in clinical programs shapes its value more than any current sales figures.
Founding and Business Approach
The company began in April 2014 under the leadership of Dr. Jeremy Levin, a physician with prior experience as global chief executive at Teva Pharmaceuticals, and Dr. Matthew During, a neuroscientist specializing in gene therapy. Its name draws from the Roman poet Ovid and his work The Metamorphoses, reflecting the founders’ aim to transform outcomes for patients facing neurological challenges. Headquartered in New York, New York, Ovid trades publicly on the Nasdaq exchange.
Like many development-stage biotech firms, Ovid generates limited income from royalties and licensing rather than product sales. It has recorded ongoing net losses and relies on equity financing along with collaborative deals to support its research efforts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Its scientific work emphasizes restoring balance in brain signaling pathways. Lead programs include OV329, a GABA-aminotransferase inhibitor under evaluation for drug-resistant epilepsies and related seizure disorders; OV350 and OV4071, compounds that activate KCC2 to support neuronal inhibition and target psychosis tied to Parkinson’s disease or Lewy body dementia; and a wider library of KCC2 activators intended for various central nervous system conditions.
Collaborations have played a role in advancing or monetizing assets, including prior agreements with Takeda Pharmaceutical and other partners. These arrangements can deliver milestone payments and royalties that help offset development costs.
Why the Stock Draws Attention
Investors follow OVID for its concentrated exposure to a differentiated neuroscience pipeline that addresses areas with limited treatment options. The emphasis on potentially first-in-class mechanisms provides a competitive edge and opens doors to future partnerships with larger pharmaceutical companies. From what I see, this setup creates multiple paths for value creation through internal progress and external deals, though outcomes remain uncertain.
Risks Worth Considering
Investing in a clinical-stage biotech like Ovid carries notable uncertainties. The absence of approved products means revenue stays low, and continued operations depend on securing fresh capital through equity raises, debt, or new alliances. Clinical development involves inherent unpredictability, with candidates at risk of setbacks related to safety, efficacy, or regulatory hurdles. The company also competes against larger players in the epilepsy and neuroscience space, where approval timelines can stretch and success is never assured.
Using AI Tools in My Analysis
When evaluating development-stage names like this one, I sometimes cross-reference data points with Tickeron’s AI Screener. The platform lets users apply technical indicators, fundamentals, volatility measures, trends, AI signals, and custom filters across thousands of stocks and ETFs. It helps surface ideas that align with specific strategies without replacing deeper fundamental review. In my view, this kind of tool supports more efficient screening when building or refining a watchlist.
Conclusion
Ovid Therapeutics remains an early-stage biopharmaceutical company pursuing novel therapies for challenging neurological and neuropsychiatric disorders. Its approach centers on GABA-AT inhibition and KCC2 activation, supported by a partnership-oriented model that can provide additional funding. For investors, OVID offers a high-risk profile closely linked to clinical milestones and ongoing financing needs.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
OVID's Stochastic Oscillator is remaining in overbought zone for 1 day
Expect a price pull-back in the near future.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OVID declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
OVID broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for OVID entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where OVID's RSI Oscillator exited the oversold zone, 22 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on OVID as a result. In 76 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for OVID just turned positive on October 21, 2026. Looking at past instances where OVID's MACD turned positive, the stock continued to rise in 46 of 52 cases over the following month. The odds of a continued upward trend are 88%.
OVID moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +14.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where OVID advanced for three days, in 207 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.652) is normal, around the industry mean (3.498). P/E Ratio (-13.571) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (204.082) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. OVID’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OVID’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Provides medicines to children and adults with neurological disorders
Industry Biotechnology
Advertisement